Diabetes self-management, an integral part of diabetes care, can be improved with the help of digital self-management tools such as apps, sensors, websites, and social media. The study objective was to reach a consensus on the criteria required to assess and recommend digital diabetes self-management tools targeting those with diabetes in Norway. Healthcare professionals working with diabetes care from all health regions in Norway were recruited to participate in a three-round Delphi study. In all rounds, the panellists rated criteria identified in a systematic review and interviews on a scale from 0-10, with the option to provide comments. On a scale of 0:not important to 10:extremely important, the highest rated criteria for assessing and recommending digital diabetes self-management tools were "Usability" and "Information quality", respectively. For assessing apps, "Security and privacy" was one of the lowest rated criteria. Having access to a list of criteria for assessing and recommending digital self-management tools can help diabetes care stakeholders to make informed choices in recommending and choosing suitable apps, websites, and social media for self-management. Future work on quality assessment of digital health tools should place emphasis on security and privacy compliance, to enable diabetes care stakeholders focus on other relevant criteria to recommend or choose and use such tools.

Download full-text PDF

Source
http://dx.doi.org/10.3233/SHTI210299DOI Listing

Publication Analysis

Top Keywords

diabetes care
16
self-management tools
16
criteria assessing
12
assessing recommending
12
recommending digital
12
digital diabetes
12
diabetes self-management
12
rated criteria
12
diabetes
9
delphi study
8

Similar Publications

Factors Associated With Semaglutide Initiation Among Adults With Obesity.

JAMA Netw Open

January 2025

Department of Global Health, School of Public Health, Boston University, Boston, Massachusetts.

Importance: Semaglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist medication, was approved for weight management in individuals with obesity in June 2021. There is limited evidence on factors associated with uptake among individuals in this subgroup without diabetes.

Objective: To explore factors associated with semaglutide initiation among a population of commercially insured individuals with obesity but no diagnosed diabetes.

View Article and Find Full Text PDF

Importance: No large randomized clinical trial has directly compared empagliflozin with dapagliflozin, leaving their comparative effectiveness regarding kidney outcomes unknown.

Objective: To compare kidney outcomes between initiation of empagliflozin vs dapagliflozin in adults with type 2 diabetes who were receiving antihyperglycemic treatment.

Design, Setting, And Participants: This target trial emulation used nationwide, population-based routinely collected Danish health care data to compare initiation of empagliflozin vs dapagliflozin in adults with type 2 diabetes who received antihyperglycemic treatment between June 1, 2014, and October 31, 2020.

View Article and Find Full Text PDF

Synergistic effect of canine FGF-21 combined with insulin in the treatment of canine diabetes.

Naunyn Schmiedebergs Arch Pharmacol

January 2025

Biopharmaceutical Lab, College of Life Science, Northeast Agricultural University, Harbin, 150030, China.

Previous studies have shown that FGF-21 can ameliorate hyperglycemia and improve the level of oxidative stress in vivo in diabetic mice. The hypoglycemic effect is safe and lasting, but it takes a longer time to exert its effect. Insulin treatment of canine diabetes takes effect quickly; however, its action time is short, and it is prone to cause hypoglycemia.

View Article and Find Full Text PDF

[Diabetes mellitus and obesity: risk optimization before surgical interventions].

Orthopadie (Heidelb)

January 2025

Westdeutsches Diabetes- und Gesundheitszentrum, Verbund Katholischer Kliniken Düsseldorf, Hohensandweg 37, 40591, Düsseldorf, Deutschland.

Background: The prevalence of obesity has increased significantly in recent years and is a causal risk factor for the development of type 2 diabetes. Moreover, chronic degenerative joint diseases are also triggered by obesity.

Weight Loss: Both obesity-related secondary diseases-type 2 diabetes and chronic degenerative joint disease-can be prevented or at least delayed by lifestyle intervention aimed at weight reduction.

View Article and Find Full Text PDF

Tailoring Exercise Prescription for Effective Diabetes Glucose Management.

J Clin Endocrinol Metab

January 2025

Department of Kinesiology and Health, Rutgers University, New Brunswick, NJ 08901, USA.

Context: Physical activity, exercise, or both are a staple of lifestyle management approaches both for type 1 diabetes mellitus (T1DM) and type 2 diabetes (T2DM). While the current literature supports both physical activity and exercise for improving glycemic control, reducing cardiovascular risk, maintaining proper weight, and enhancing overall well-being, the optimal prescription regimen remains debated.

Evidence Acquisition: We searched PubMed and Google Scholar databases for relevant studies on exercise, insulin sensitivity, and glycemic control in people with T1DM and T2DM.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!